Current strategies for treating infants with severe bronchopulmonary dysplasia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue SUPPL. 3, 2012, Pages 15-20

  Papoff, Paola ^a   Cerasaro, Carla ^a   Caresta, Elena ^a   Barbàra, Caterina Silvia ^a   Midulla, Fabio ^a   Moretti, Corrado ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bronchopulmonary dysplasia; Corticosteroids; Pulmonary hypertension; Severe; Treatment; Ventilation

Indexed keywords

BOSENTAN; BRONCHODILATING AGENT; CORTICOSTEROID; DEXAMETHASONE; ILOPROST; NITRIC OXIDE; OXYGEN; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL;

ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; DISEASE SEVERITY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; GAS EXCHANGE; HUMAN; HYPOXEMIA; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG DYSPLASIA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG RESISTANCE; NUTRITIONAL ASSESSMENT; OXYGEN SATURATION; OXYGEN SUPPLY; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTEMATIC REVIEW; TRACHEOSTOMY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

BRONCHOPULMONARY DYSPLASIA; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY THERAPY;

EID: 84866977601     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.712352     Document Type: Review

References (65)

1. Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol 2006;30:179-184.
2. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641-643.
3. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-368.
4. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353-1360.
5. Farstad T, Bratlid D, Medb?S, Markestad T; Norwegian Extreme Prematurity Study Group. Bronchopulmonary dysplasia-prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatr 2011;100:53-58.
6. Kovesi T, Abdurahman A, Blayney M. Elevated carbon dioxide tension as a predictor of subsequent adverse events in infants with bronchopulmonary dysplasia. Lung 2006;184:7-13.
7. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007;120:1260-1269.
8. Abman SH, Burchell MF, Schaffer MS, Rosenberg AA. Late sudden unexpected deaths in hospitalized infants with bronchopulmonary dysplasia. Am J Dis Child 1989;143:815-819.
9. Greenough A. Long-term pulmonary outcome in the preterm infant. Neonatology 2008;93:324-327.
10. Ambalavanan N, Carlo WA. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006;30:192-199.
11. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006;367:1421-1431.
12. Yuksel B, Greenough A. Variable response to bronchodilator therapy in young children born prematurely. Respir Med 1993;87:359-364.
13. Doull IJ, Mok Q, Tasker RC. Tracheobronchomalacia in preterm infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1997;76:F203-F205.
14. Loring SH, O'donnell CR, Feller-Kopman DJ, Ernst A. Central airway mechanics and flow limitation in acquired tracheobronchomalacia. Chest 2007;131:1118-1124.
15. Panitch HB, Allen JL, Alpert BE, Schidlow DV. Effects of CPAP on lung mechanics in infants with acquired tracheobronchomalacia. Am J Respir Crit Care Med 1994;150:1341-1346.
16. Greenough A, Donn SM. Matching ventilatory support strategies to respiratory pathophysiology. Clin Perinatol 2007;34:35-53, v.
17. Miller JD, Carlo WA. Safety and effectiveness of permissive hypercapnia in the preterm infant. Curr Opin Pediatr 2007;19:142-144.
18. Schroeder JW Jr, Schneider JS, Walner DL. The influence of peak airway pressure and oxygen requirement on infant tracheostomy. Int J Pediatr Otorhinolaryngol 2012;76:869-872.
19. Pierson DJ. Tracheostomy and weaning. Respir Care 2005;50:526-533.
20. Wong YC, Beardsmore CS, Meek JH, Stocks J, Silverman M. Bronchial hypersecretion in preterm neonates. Arch Dis Child 1982;57:117-122.
21. Dulguerov P, Gysin C, Perneger TV, Chevrolet JC. Percutaneous or surgical tracheostomy: a meta-analysis. Crit Care Med 1999;27:1617-1625.
22. Carron JD, Derkay CS, Strope GL, Nosonchuk JE, Darrow DH. Pediatric tracheotomies: changing indications and outcomes. Laryngoscope 2000;110:1099-1104.
23. Pereira KD, MacGregor AR, McDuffie CM, Mitchell RB. Tracheostomy in preterm infants: current trends. Arch Otolaryngol Head Neck Surg 2003;129:1268-1271.
24. Chelius DC, Kocdor P, Elidemir O, Giannoni CM. Tracheostomy in bronchopulmonary dysplasia. Otolaryngol Head Neck Surg 2008; 139(2 Suppl):P163-164.
25. Bancalari E, Wilson-Costello D, Iben SC. Management of infants with bronchopulmonary dysplasia in North America. Early Hum Dev 2005;81:171-179.
26. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009;(1):CD001145.
27. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009; CD001146
28. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 2012;185:12-23.
29. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; CD001146
30. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001144.
31. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001145.
32. Watterberg KL; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010;126:800-808.
33. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115:655-661.
34. DeCastro M, El-Khoury N, Parton L, Ballabh P, LaGamma EF. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol 2009;29:297-304.
35. Pantalitschka T, Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol 2006;41:703-708.
36. Onland W, Offringa M, van Kaam A. Late (= 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2012;4:CD002311.
37. Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008;121:e1310-e1318.
38. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995;95:120-125.
39. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:111-117.
40. Tin W, Wiswell TE. Adjunctive therapies in chronic lung disease: examining the evidence. Semin Fetal Neonatal Med 2008;13:44-52.
41. Kao LC, Durand DJ, Nickerson BG. Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989;6:74-80.
42. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;CD001817.
43. Frakaloss G, Burke G, Sanders MR. Impact of gastroesophageal reflux on growth and hospital stay in premature infants. J Pediatr Gastroenterol Nutr 1998;26:146-150.
44. Wang LY, Luo HJ, Hsieh WS, Hsu CH, Hsu HC, Chen PS, Chiu NC, et al. Severity of bronchopulmonary dysplasia and increased risk of feeding desaturation and growth delay in very low birth weight preterm infants. Pediatr Pulmonol 2010;45:165-173.
45. Giuffre RM, Rubin S, Mitchell I. Antireflux surgery in infants with bronchopulmonary dysplasia. Am J Dis Child 1987;141:648-651.
46. Fouron JC, Le Guennec JC, Villemant D, Perreault G, Davignon A. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics 1980;65:529-535.
47. Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins JW Jr. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 1985;75:80-84.
48. Harrod JR, L'Heureux P, Wangensteen OD, Hunt CE. Long-term follow-up of severe respiratory distress syndrome treated with IPPB. J Pediatr 1974;84:277-285.
49. Berman W Jr, Yabek SM, Dillon T, Burstein R, Corlew S. Evaluation of infants with bronchopulmonary dysplasia using cardiac catheterization. Pediatrics 1982;70:708-712.
50. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006;367(9520):1421-1431.
51. Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988;112:67-72.
52. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-1729.
53. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008;121:317-325.
54. Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child 2008;93:620-625.
55. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008;121(2):317-325.
56. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999;103:610-618.
57. de Visser YP, Walther FJ, Laghmani el H, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 2009;10:30.
58. Nyp M, Sandritter T, Poppinga N, Simon C, Truog WE. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefitS J Perinatol 2012;32:64-69.
59. Caputo S, Furcolo G, Rabuano R, Basilicata AM, Pilla LM, De Simone A, Pasquariello B, et al. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. J Cardiovasc Med (Hagerstown) 2010;11:704-706.
60. Hon KL, Cheung KL, Siu KL, Leung TF, Yam MC, Fok TF, Ng PC. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate 2005;88:109-112.
61. Zaidi AN, Dettorre MD, Ceneviva GD, Thomas NJ. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Pediatr Pulmonol 2005;40:265-269.
62. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008;8:171-185.
63. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704.
64. Choudhary G, Troncales F, Martin D, Harrington EO, Klinger JR. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. J Heart Lung Transplant 2011;30:827-833.
65. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082-1086.